A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILUMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY IN ADULT PARTICIPANTS WITH MODERATE-TOSEVERE PRIMARY DISCOID LUPUS ERYTHEMATOSUS

Registry ID

HZNP-DAX-202

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

HORIZON THERAPEUTICS IRELAND DAC

Start date

2023-10-27

Last update

2022-06-23

Conditions

• DISCOID LUPUS ERYTHEMATOSUS

Related clinical trials

• A PHASE 2, SINGLE-BLIND, INTRAINDIVIDUAL STUDY TO EVALUATE THE EFFICACY OF RUXOLITINIB 1.5% CREAM IN ADULT SUBJECTS WITH DISCOID LUPUS ERYTHEMATOSUS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY ASSESSING THE EFFICACY AND SAFETY OF THE RIPK1-INHIBITOR SAR443122 IN PATIENTS WITH MODERATE TO SEVERE SUBACUTE OR DISCOID/CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS

View on source registry